A Phase 1 Clinical Trial to Evaluate the Phototoxic Potential of Delgocitinib Cream After Single Topical Occlusive Application on Healthy Skin
Latest Information Update: 05 Nov 2020
At a glance
- Drugs Delgocitinib (Primary)
- Indications Alopecia areata; Atopic dermatitis; Autoimmune disorders; Discoid lupus erythematosus; Eczema; Hypersensitivity; Inverse psoriasis
- Focus Adverse reactions
- Sponsors LEO Pharma
Most Recent Events
- 08 Jun 2020 Status changed from not yet recruiting to completed.
- 27 Apr 2020 New trial record